Philadelphia Financial Management of San Francisco LLC Grows Stock Holdings in ASP Isotopes Inc. (NASDAQ:ASPI)

Philadelphia Financial Management of San Francisco LLC increased its stake in ASP Isotopes Inc. (NASDAQ:ASPI) by 158.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 991,863 shares of the company’s stock after buying an additional 607,893 shares during the quarter. Philadelphia Financial Management of San Francisco LLC’s holdings in ASP Isotopes were worth $2,757,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of ASP Isotopes by 479.1% in the first quarter. Vanguard Group Inc. now owns 1,021,019 shares of the company’s stock worth $4,217,000 after acquiring an additional 844,705 shares during the last quarter. HTLF Bank boosted its stake in ASP Isotopes by 197.0% in the 2nd quarter. HTLF Bank now owns 105,538 shares of the company’s stock worth $323,000 after purchasing an additional 70,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in ASP Isotopes during the 2nd quarter valued at about $381,000. Fielder Capital Group LLC purchased a new stake in ASP Isotopes during the 2nd quarter valued at about $55,000. Finally, Rhumbline Advisers bought a new stake in ASP Isotopes during the 2nd quarter valued at about $116,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $4.89 on Wednesday. The company has a quick ratio of 7.54, a current ratio of 7.55 and a debt-to-equity ratio of 0.80. The firm’s 50-day moving average price is $5.34 and its 200-day moving average price is $3.94. ASP Isotopes Inc. has a 52-week low of $1.65 and a 52-week high of $9.33. The company has a market cap of $349.10 million, a PE ratio of -8.02 and a beta of 3.27.

Analysts Set New Price Targets

ASPI has been the topic of several analyst reports. Canaccord Genuity Group started coverage on shares of ASP Isotopes in a research note on Friday, October 4th. They issued a “buy” rating and a $4.50 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $4.50 target price on shares of ASP Isotopes in a research note on Friday, October 18th. Finally, HC Wainwright decreased their price target on ASP Isotopes from $5.50 to $4.50 and set a “buy” rating for the company in a research note on Wednesday, August 7th.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.